“Honest And Straightforward” 483 Responses May Avert Warning Letters
Executive Summary
CDER is weighing companies' responses to FDA-483 inspection reports in considering whether to issue warning letters, Center for Drug Evaluation & Research Office of Compliance Director David Horowitz said